FDA warns YangZhou SuXiang Medical Instrument over manufacturing quality failures and import alert for OTC drugs.
What happened
FDA found the problems by reviewing records the company submitted after FDA's August 15, 2022 request for records under section 704(a)(4); the letter does not describe an inspection. FDA found no demonstration of incoming component identity testing, incomplete process validation before U.S. distribution, and inadequate finished-product release testing, including active ingredient identity and strength. FDA also placed the firm on Import Alert 66-40 on July 1, 2024.
What FDA found
The firm did not show that it tests the identity of each incoming component before using it to make drugs.
21 CFR 211.84(d)(1)The firm lacked adequate written production and process control procedures, had incomplete process validation, shipped to the U.S. before validation, and its quality unit did not ensure processes were validated and controlled before release.
21 CFR 211.100(a)The firm did not show adequate finished-product release testing, including identity and strength of active ingredients, before release.
21 CFR 211.165(a)
What FDA wants
FDA tells the company to correct the violations promptly and reply in writing within 15 working days with what it has done and how recurrence will be prevented; if it cannot finish, it must explain the delay and give a schedule.
Who should pay attention
- brands that buy OTC drugs from this manufacturer
- U.S. distributors of OTC drug products and pads
- quality teams handling supplier qualification for Chinese OTC drug makers
This is a summary. Read the original letter on fda.gov.